Back to search results

Studying Microvascular Dysfunction After Gestational Diabetes

This study is looking at how a history of gestational diabetes (GDM), a type of diabetes that can develop during pregnancy, affects small blood vessel (microvascular) function. Researchers want to understand the role of a substance called ET-1, physical activity, and sedentary behavior in this process. They will test how different concentrations of insulin aspart, a type of insulin, affect blood vessel dilation. The study aims to enroll 40 women, aged 18-50, who have been pregnant within the last 5 years and either had a healthy pregnancy or were diagnosed with GDM. The main goal is to measure the amount of microvascular dilation caused by insulin at a single study visit, lasting about 4 hours. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 40 women. It is not specified if it is randomized or blinded.
What's involved
Participants will attend one study visit lasting approximately 4 hours. During this visit, insulin aspart will be administered at increasing concentrations.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at the study visit, which is an average of 4 hours.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06547619

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

Recruiting
EARLY_PHASE1Ages 18–50InterventionalBasic science
Anna Stanhewicz, PhD
~40 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Insulin aspart

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
amount of microvascular insulin-mediated dilation
Measured over at the study visit, an average of 4 hours

Conditions

Gestational Diabetes
Endothelial Dysfunction
Physical Inactivity

Explore related trials

Endothelial dysfunctionGestational Diabetes

Where it's being run

1 sites across 1 states
Iowa1

Who to contact

Anna Reid-Stanhewicz, PHD
[email protected]
319-467-1732
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

history of pregnancy within 5 years of the study visit
had healthy pregnancy OR had gestational diabetes diagnosed by their obstetrician and confirmed according to the American College of Obstetricians and Gynecologists criteria for gestational diabetes.

Exclusion

skin diseases,
current tobacco or electronic cigarette/vape pen use,
diagnosed or suspected hepatic or metabolic disease including diabetes,
statin or other cholesterol-lowering medication,
current antihypertensive medication,
history of preeclampsia or gestational hypertension
current hypertension,
current pregnancy,
body mass index \<18.5 kg/m2,
allergy to materials used during the experiment.(e.g. latex), known allergies to study drugs.

What this trial measures

  • amount of microvascular insulin-mediated dilationat the study visit, an average of 4 hours

    cutaneous vascular vasodilator responses to insulin perfusion in lactated Ringer's, BQ 788 and BQ-123, and L-NAME treated microdialysis sites